A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
Latest Information Update: 13 Feb 2024
At a glance
- Drugs GSK-3888550A (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms RSV MAT-012
- Sponsors GlaxoSmithKline Biologicals; GSK
- 11 Feb 2024 Status changed from completed to discontinued ( Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSVMAT 009), GSK made the decision to stop enrolment and vaccination in the study).
- 30 Jun 2023 Status changed from active, no longer recruiting to completed.
- 11 Mar 2023 This trial has been completed in Finland, according to European Clinical Trials Database record.